ANDA 207182, held by Eugia Pharma. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 207182 (Lidocaine Hydrochloride), held by Eugia Pharma, was first approved by FDA on Oct 30, 2017, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine hydrochloride injection is indicated for production of local or regional anesthesia by infiltration techniques, such as percutaneous injection, and by peripheral nerve block techniques such as brachial plexus and intercostal, when the accepted procedures for these techniques as described in standard textbooks are observed.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2017 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Oct 29, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 30, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters